The Lynx Group
Cholangiocarcinoma News

Comparison of the Clinical Features, Treatment Patterns, and Tumor Mutations of Patients with Intrahepatic and Extrahepatic CCA

2020 Year in Review: Cholangiocarcinoma — December 19, 2020

Retrospective chart review data indicate that intrahepatic CCA and extrahepatic CCA exhibit disparate clinical features and molecular profile, and divergent treatment patterns.

To inform treatment decision, better insights on the clinical and molecular features distinguishing patients with intrahepatic CCA and extrahepatic CCA are warranted. Results of a retrospective chart review that compared the clinicopathologic and molecular characteristics of intrahepatic CCA and extrahepatic CCA as well as treatment patterns were reported at the ASCO 2020 Gastrointestinal Cancers Symposium and summarized here.

A retrospective chart review was performed at 8 institutions on patients with histologically confirmed intrahepatic CCA or extrahepatic CCA diagnosed after June 2009. Information relating to demographics, risk factors, treatments, pathology, and OS was collected. Molecular profiling of tumor tissue was also performed.

A total of 737 patients with CCA were enrolled. Of these, 538 (73%) had a diagnosis of intrahepatic CCA and 199 (27%) had extrahepatic CCA. Compared with the extrahepatic CCA cohort, patients in the intrahepatic CCA cohort were significantly more likely to be female (52% vs 42%; P = .013), present with lymph node metastasis (35% vs 22%; P = .0004), have solid organ metastasis primarily to the liver (85% vs 58%; P <.0001) or lung (37% vs 14%; P = .0011), have tumors ≥5 cm at resection (47.5% vs 5%; P <.0001), and have a larger tumor size (5.5 cm vs 2.5 cm; P <.0001). In terms of treatment pattern, patients in the intrahepatic CCA cohort more often received liver-directed therapy (45% vs 26%; P = .0004), targeted therapy (17% vs 4%; P = .0002), and were more often enrolled in a clinical trial (23% vs 11%; P = .004). In comparison with the intrahepatic CCA cohort, patients in the extrahepatic CCA cohort were more likely to be male (58% vs 48%; P = .013), have peritoneal metastasis (35% vs 25%; P = .0343), undergone surgery (55% vs 30%; P <.0001), and receive adjuvant chemoradiation (80% vs 29%; P <.0001).

Mutation profiling was performed in 381 (52%) patients. Of these, 301 patients had intrahepatic CCA and 80 had extrahepatic CCA. The findings of the molecular analysis indicated that patients with intrahepatic CCA were significantly more likely to have IDH1 mutations (P <.0001) and FGFR2 fusions (P = .0004), whereas patients with extrahepatic CCA were more likely to have KRAS mutations (P = .0004), APC mutations (P = .0027), SMAD4 mutations (P = .0051), and TP53 mutations (P = .043).

These data indicate that patients with intrahepatic CCA and extrahepatic CCA show differences in their clinical features and molecular profiling, leading to disparate treatment patterns.

Source: Pappas L, et al. J Clin Oncol. 2020;38(4_suppl). Abstract 580.

Related Items

Accelerated Approval Granted for Infigratinib for the Treatment of Metastatic Cholangiocarcinoma
Web Exclusives
Infigratinib has been approved to treat adults with previously treated locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement.
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
March 2021, Vol 2, No 1
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
The Oncology Pipeline Offers Hope for Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Despite the onslaught of the COVID-19 pandemic, researchers are hard at work to develop innovative therapies that will make a difference in the lives of patients with cancer.
Genomic Testing in Cholangiocarcinoma: Look for Actionable Molecular Alterations
December 2020, Vol 1, No 3
At the 2020 Cholangiocarcinoma Summit, Nabeel El-Bardeesy, PhD, Associate Professor, Medicine, Harvard Medical School, and Associate Geneticist, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, moderated a session titled “Molecular Biomarkers in CCA: Focus on Current and Emerging Technologies.” The session focused on how best to integrate the array of genomic testing platforms into clinical practice. The session included 2 presenters who discussed this topic.
Increasing Number of Biomarkers Being Studied in Cholangiocarcinoma Clinical Trials
December 2020, Vol 1, No 3
At diagnosis, the majority of patients with intrahepatic cholangiocarcinoma (CCA) present with advanced disease and a poor prognosis. Comprehensive genomic profiling (CGP) of intrahepatic CCA has revealed multiple potential therapeutic targets, including FGFR2, ERBB2 (HER2), and IDH1. Therefore, performing CGP early in the disease course is critical to increasing first-line clinical trial enrollment and access to treatment with FGFR inhibitors.
Managing Cholangiocarcinoma in the Setting of COVID-19: Unique Challenges and Opportunities
By Ghassan K. Abou-Alfa, MD, MBA; Bruce Lin, MD; Farshid Dayyani, MD, PhD; Richard Kim, MD; Rachna T. Shroff, MD, MS; Melinda Bachini; Milind M. Javle, MD
December 2020, Special Issue: Managing CCA in the Setting of COVID-19
The first confirmed case in the United States of the 2019 novel coronavirus (COVID-19) was reported on January 21, 2020, and as of November 27, 2020, there were >63 million confirmed cases and >1.5 million deaths globally. Despite the global impact, certain populations have been identified as having a higher risk of developing severe COVID-19 infection, including patients with cancer. Various studies have shown that patients with cancer experience particularly poor outcomes after COVID-19 infection. As a result of the pandemic, care delivery has been disrupted to some degree based on the need for prioritization and limitations on resources. Therefore, healthcare providers and patients have been continually reassessing the balance between the benefits and risks of anticancer interventions in the context of the added risk of COVID-19 infection.
Cholangiocarcinoma Year in Review Introduction
2020 Year in Review: Cholangiocarcinoma
As a result of the COVID-19 pandemic, year 2020 has witnessed unprecedented changes in the practice of medicine. The effect on medical conferences has been equally dramatic, and several major meetings have been canceled or altered. Fortunately, the oncology community adapted quickly!
Toripalimab, Lenvatinib, plus Chemotherapy a Promising Combination in Advanced Unresectable Intrahepatic CCA
2020 Year in Review: Cholangiocarcinoma
The multidrug combination of toripalimab, lenvatinib plus chemotherapy with gemcitabine and oxaliplatin showed promising efficacy and tolerability in patients with intrahepatic CCA.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: